- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04228887
Effects of Inspiratory Muscle Training in Patients With Parkinson's Disease
Effects of Inspiratory Muscle Training on Postural Stability, Mobility, Activities of Daily Living, Quality of Life and Respiratory Function in Patients With Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Bezmialem Vakif University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with Parkinson'S Disease
- Ages between 60 and 85 years
- Grades 1 to 3 according to Modified Hoehn-Yahr Scale
Exclusion Criteria:
- Lung surgery or diagnosed lung disease history
- Dementia
- Having a orthopedic disorder which may affect balance and/or mobility
- Severe dyskinesia and cognition problems
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Control Group
The control group will be receive 45 minutes training sessions 3 times a week for 8 weeks; 2 days a week for home based balance training and 1 day for supervisory training with Bio-Dex Balance-System ®.
|
Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
Balance training will provide with Biodex® Balance Training System
|
ACTIVE_COMPARATOR: Training Group
The training group will receive inspiratory muscle training; 15 minutes sessions 5 times a week for 8 weeks in addion to balance training same as control.
|
Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
Balance training will provide with Biodex® Balance Training System
15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inspiratory Muscle Strength
Time Frame: Change from baselines to final evaluation at 8th weeks
|
Maximal inspiratory pressure (MIP) is the most widely used measure of respiratory muscle strength in patients with suspected respiratory muscle weakness.
It is determined by measuring upper airway pressure (mouth for outpatients and trachea for intubated or tracheostomized patients) during a maximal voluntary inspiratory effort.
The measured pressure is a composite of the pressure generated by the inspiratory muscles and the elastic recoil pressure of the lungs and chest wall.
|
Change from baselines to final evaluation at 8th weeks
|
Respiratory Function- Forced Vital Capasity (FVC)
Time Frame: Change from baselines to final evaluation at 8th weeks
|
Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test.
FVC can also help doctors assess the progression of lung disease and evaluate the effectiveness of treatment.
|
Change from baselines to final evaluation at 8th weeks
|
Respiratory Function- Forced Expiratory Volume in 1 second
Time Frame: Change from baselines to final evaluation at 8th weeks
|
Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced expiratory volume and forced vital capacity are lung function tests that are measured during spirometry. Forced expiratory volume is the most important measurement of lung function. It is used to: Diagnose obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). A person who has asthma or COPD has a lower FEV1 result than a healthy person. See how well medicines used to improve breathing are working. Check if lung disease is getting worse. Decreases in the FEV1 value may mean the lung disease is getting worse. |
Change from baselines to final evaluation at 8th weeks
|
Respiratory Function- Peak Expiratory Flow
Time Frame: Change from baselines to final evaluation at 8th weeks
|
The peak expiratory flow (PEF), also called peak expiratory flow rate (PEFR), is a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air.
|
Change from baselines to final evaluation at 8th weeks
|
Postural Control and Balance
Time Frame: Change from baselines to final evaluation at 8th weeks
|
Biodex Balance System evaluations
|
Change from baselines to final evaluation at 8th weeks
|
Parkinson's Status- Unified Parkinson's Disease Rating Scale
Time Frame: Change from baselines to final evaluation at 8th weeks
|
The UPDRS scale refers to Unified Parkinson Disease Rating Scale, and it is a rating tool used to gauge the course of Parkinson's disease in patients.
The UPDRS scale includes series of ratings for typical Parkinson's symptoms that cover all of the movement hindrances of Parkinson's disease.
The UPDRS scale consists of the following five segments: 1) Mentation, Behavior, and Mood, 2) ADL, 3) Motor sections, 4) Modified Hoehn and Yahr Scale, and 5) Schwab and England ADL scale.
Each answer to the scale is evaluated by a medical professional that specializes in Parkinson's disease during patient interviews.
|
Change from baselines to final evaluation at 8th weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mobility Status- Rivermead mobility index
Time Frame: Change from baselines to final evaluation at 8th weeks
|
The Rivermead Mobility Index assesses functional mobility in gait, balance and transfers. The Rivermead Mobility Index is appropriate for a range of disabilities that include anything from being bedridden to being able to run 15 items: 14-self-reported items 1 direct observation item Items progress in difficulty Items are coded as either 0 or 1, depending on whether the patient can complete the task according to specific instructions Items receive a score of 0 for a "No" response and 1 for a "Yes" response Total scores are determined by summing the points for all items A maximum of 15 points is possible; higher scores indicate better mobility performance A score of "0" indicates an inability to perform any of the activities on the measure |
Change from baselines to final evaluation at 8th weeks
|
Quality of Life Parameter-Nottingham Health Profile
Time Frame: Change from baselines to final evaluation at 8th weeks
|
The Nottingham Health Profile is intended for primary health care, to provide a brief indication of a patient's perceived emotional, social and physical health problems. Breakdown of questionaire (1) Part I: 38 questions in 6 subareas, with each question assigned a weighted value; the sum of all weighted values in a given subarea adds up to 100
|
Change from baselines to final evaluation at 8th weeks
|
Activities of Daily Living-Barthel
Time Frame: Change from baselines to final evaluation at 8th weeks
|
The Barthel Scale/Index (BI) is an ordinal scale used to measure performance in activities of daily living (ADL).
Ten variables describing ADL and mobility are scored, a higher number being a reflection of greater ability to function independently following hospital discharge.Time taken and physical assistance required to perform each item are used in determining the assigned value of each item.
The Barthel Index measures the degree of assistance required by an individual on 10 items of mobility and self care ADL.
|
Change from baselines to final evaluation at 8th weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hülya N Gürses, Prof, Bezmialem Vakif University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BezmialemVU27
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Respiratory Muscle Strength
-
University of FloridaCompleted
-
Vanderbilt University Medical CenterNot yet recruitingDysphagia | Heart Transplant Recipients
-
University of South FloridaNot yet recruitingDyspnea | Post-COVID-19 SyndromeUnited States
-
Duke UniversityCompleted
-
Pamukkale UniversityCompletedInjury | Core Stability | Respiratory Muscle Strength | Functional Movement QualityTurkey
-
Nova Southeastern UniversityCongressionally Directed Medical Research ProgramsRecruitingRespiratory Insufficiency | Dysphagia | ALSUnited States
-
Bezmialem Vakif UniversityCompletedCystic Fibrosis | Primary Ciliary DyskinesiaTurkey
-
Istanbul University - Cerrahpasa (IUC)RecruitingPediatric-onset Multiple SclerosisTurkey
-
Ankara Yildirim Beyazıt UniversityUnknownDisabilities MultipleTurkey
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom